Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 15, 2014, 114 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $538.00 to $2,081,081.25.

Highlighted Stocks Traded by Insiders:

Intercept Pharmaceuticals (ICPT) - FREE Research Report

Benatti Luca, who is Director at Intercept Pharmaceuticals, bought 800 shares at $139.86 on Dec. 15, 2014. Following this transaction, the Director owned 1,292 shares meaning that the stake was boosted by 162.6% with the 800-share transaction.

The shares most recently traded at $133.91, down $5.95, or 4.44% since the insider transaction. Historical insider transactions for Intercept Pharmaceuticals go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 790
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 790
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 3,997

The average volume for Intercept Pharmaceuticals has been 540,400 shares per day over the past 30 days. Intercept Pharmaceuticals has a market cap of $3.0 billion and is part of the health care sector and drugs industry. Shares are up 101.66% year-to-date as of the close of trading on Friday.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. Currently, there are 6 analysts who rate Intercept Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ICPT - FREE

TheStreet Quant Ratings

rates Intercept Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full

Intercept Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

BofI (BOFI) - FREE Research Report

Burke John Gary, who is Director at BofI, sold 7,100 shares at $77.50 on Dec. 15, 2014. Following this transaction, the Director owned 455,495 shares meaning that the stake was reduced by 1.53% with the 7,100-share transaction.

The shares most recently traded at $79.01, up $1.51, or 1.91% since the insider transaction. Historical insider transactions for BofI go as follows:

  • 4-Week # shares bought: 645
  • 4-Week # shares sold: 3,801
  • 12-Week # shares bought: 645
  • 12-Week # shares sold: 3,801
  • 24-Week # shares bought: 645
  • 24-Week # shares sold: 9,801

The average volume for BofI has been 233,700 shares per day over the past 30 days. BofI has a market cap of $1.1 billion and is part of the financial sector and banking industry. Shares are down 1.54% year-to-date as of the close of trading on Friday.

BofI Holding, Inc. operates as the holding company for BofI Federal Bank that provides consumer and business banking products through the Internet in the United States. The company has a P/E ratio of 18.4. Currently, there are 4 analysts who rate BofI a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BOFI - FREE

TheStreet Quant Ratings

rates BofI as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

BofI Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

JG Wentworth Company (JGW) - FREE Research Report

Trishield Special Situations Master Fund Ltd., who is 10% Owner at JG Wentworth Company, bought 197,847 shares at $8.71 on Dec. 15, 2014. Following this transaction, the 10% Owner owned 1.7 million shares meaning that the stake was boosted by 12.76% with the 197,847-share transaction.

The shares most recently traded at $9.29, up $0.58, or 6.3% since the insider transaction.

The average volume for JG Wentworth Company has been 132,600 shares per day over the past 30 days. JG Wentworth Company has a market cap of $134.3 million and is part of the financial sector and real estate industry. Shares are down 50.09% year-to-date as of the close of trading on Friday.

The J.G. Wentworth Company provides funding solutions to customers in the United States. The company purchases customers' structured settlement payments, annuity payments, lottery winnings, and other future payment streams, as well as provides pre-settlement funding. Currently, there are 4 analysts who rate JG Wentworth Company a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on JGW - FREE

TheStreet Quant Ratings

rates JG Wentworth Company as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk and disappointing return on equity. Get the full

JG Wentworth Company Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by

Zacks Investment Research

null